Study on 198 patients with HIV diagnosed following the criteria of Department of Health at the Infectious Department of Hospital No.103, including 55 HIV/HCV coinfection patients, by retrospective and prospective research; The authors divided patients into two groups to treat with two different drug combinations and compare the change of hepatic enzymes, bilirubin between them. The result as follows: - In the HIV/HCV coinfection group treated with d4T/3TC/EFV, the rate of the patients having an increase in hepatic enzymes were decreased with duration of treatment; - In the group treated with NVP (d4T/3TC/NVP), after 4 weeks of treatment, it made a rise in rate of the patients having the increased hepatic enzymes. Among them this rate of the HIV/HCV coinfection group was significant higher than the monoinfection (ALT: 28.9 percent and AST: 28.9 percent of the HIV/HCV coinfection group compared with ALT: 11.1 percent and AST: 12.1 percent of the monoinfection group).
- Đăng nhập để gửi ý kiến